Sontra, Bayer amend license for Sontra's continuous glucose monitor

By Ted A. Knutson

Washington, Dec. 15 - Sontra Medical Corp. announced Thursday that it has amended its license agreement with the Diabetes Care Division of Bayer Healthcare LLC to give Sontra worldwide co-exclusive rights to develop and market its continuous transdermal glucose monitoring system.

The system uses the SonoPrep ultrasonic skin permeation technology for the hospital intensive care unit (ICU) market.

In exchange, Sontra has agreed to reduce Bayer's milestone payment to Sontra due upon Bayer's completion of the first phase of product development to $2 million and will pay Bayer a royalty equal to 1% of Sontra's net product sales in the hospital ICU market.

"Sontra is best positioned to accelerate the development and commercialization of Sontra's continuous glucose monitor for the ICU, as we have completed the first prototypes and expect to begin human clinical studies in early 2006 at leading Boston hospitals. More importantly, we are on track to complete product development of the SonoPrep skin permeation and glucose sensing technology for the ICU by the end of 2006," stated Thomas W. Davison, Sontra's president and chief executive officer, in a news release.

Franklin, Mass.-Based Sontra develops transdermal drug formulation, delivery systems and biosensors.

Bayer Healthcare is a subsidiary of Leverkusen, Germany-based pharmaceutical company Bayer AG.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.